Press Releases

Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Nov 13 2018

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  additional data from a Phase 1/2 clinical study of INT230-6, the Company’s novel lead product candidate designed for direct intratumoral injection, and preclinical research highlighting the Company’s proprietary DfuseRxSM technology were presented in a poster session  at the Society for… Read more »

Intensity Therapeutics Raises $6.5 Million in Series B Financing

Nov 13 2018

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced the completion of a $6.5 million Series B financing. Intensity plans to use the proceeds of the financing to advance the clinical development of lead product candidate INT230-6, a direct intratumoral injection that is currently being evaluated in a Phase… Read more »

Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors

Oct 13 2018

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  preliminary data from a Phase 1/2 clinical study demonstrated that INT230-6, the Company’s novel lead product candidate designed for direct intratumoral injection, was well tolerated in patients with advanced solid tumors. The data were presented in a poster session on… Read more »

View All Press Releases

Publications/Papers/Posters

SITC 2018 Poster Presentation P622

Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

ESMO 2018 Poster Presentation Abstract 4458

Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

ASCO 2018 Poster Presentation TPS2609

Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies. TPS2609

View All Publications/Papers/Posters